IP Library › Granted Patent US 12,427,110
Granted Patent B2
US 12,427,110 · App. 17/172,894 · Granted Sep 30, 2025

Liposomes for inhibiting biofilm formation

Inventors: Samareh Azeredo Da Silveira Lajaunias (Geneva, CH); Frédéric Lajaunias (Geneva, CH)
Assignee: COMBIOXIN SA
A61K9/127A61K31/045A61K31/685A61K31/688A61L2/18A61L2202/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,110
App. No.
17/172,894
Granted
Sep 30, 2025
Kind
B2
Abstract

The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises, preferably consists of, at least one empty liposome selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; (b) an empty liposome consisting of sphingomyelin; and (c) an empty liposome comprising, preferably consisting of, phosphatidylcholine and sphingomyelin; and at least one empty liposome independently of each other selected from an empty liposome comprising, preferably consisting of, lipids or phospholipids selected from cholesterol, sphingomyelins, ceramides, phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, diacylglycerols, and phosphatidic acids containing one or two or more saturated or unsaturated fatty acids longer than 4 carbon atoms and up to 28 carbon atoms; for use in a method for preventing or reducing biofilm formation or for eradicating or reducing existing biofilm.

Claims (13)

1. A method for eradicating or reducing existing biofilm on a surface in a mammal in need thereof, comprising administering to the mammal, a therapeutically effective amount of a composition consisting of a mixture of empty liposomes, wherein said mixture of empty liposomes consists of

(a) a first empty liposome consisting of sphingomyelin and 35-60% (weight/weight) cholesterol; and

(b) a second empty liposome consisting of sphingomyelin,

and wherein said mixture of empty liposomes comprises at least 40% (w/w) of said first and at least 40% (w/w) of said second empty liposome.

2. The method of claim 1 , wherein the amount of cholesterol of said empty liposome (a) is 45%-55% (weight per weight).

3. The method of claim 1 , wherein said method further comprises the administration of an antimicrobial agent.

4. The method of claim 1 , wherein the amount of cholesterol of said empty liposome (a) is about 50% (weight per weight).

5. The method of claim 3 , wherein said antimicrobial agent is an antibiotic, an antifungal agent, an anti-toxin agent, an anti-virulence agent, an antiseptic, or a combination thereof.

6. An ex-vivo method for eradicating or reducing existing biofilm on a surface comprising contacting said surface with a composition consisting of a mixture of empty liposomes, wherein said mixture of empty liposomes consists of

(a) a first empty liposome consisting of sphingomyelin and 35-60% (weight/weight) cholesterol; and

(b) a second empty liposome consisting of sphingomyelin,

and wherein said mixture of empty liposomes comprises at least 40% (w/w) of said first empty liposome and at least 40% (w/w) of said second empty liposome.

7. The method of claim 6 , wherein said surface is a surface of a medical device.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2021
From: AZEREDO DA SILVEIRA LAJAUNIAS, SAMAREH; LAJAUNIAS, FRÉDÉRIC
To: COMBIOXIN SA
Reel/Frame 055244/0512 →
Priority Claims (1)
EP 17158913 · Mar 2, 2017 · regional
Continuity (2)
Continuation 16488516
Related Publication 20210275452A1 · Sep 9, 2021
References Cited (43)
US 5543152A · Webb et al. · 1996 [cited by applicant]
US 5741516A · Webb et al. · 1998 [cited by applicant]
US 8906855B2 · Simpkins · 2014 [cited by applicant]
US 9439855B2 · Simpkins · 2016 [cited by applicant]
US 10716756B2 · Simpkins · 2020 [cited by applicant]
US 10744089B2 · Babiychuk et al. · 2020 [cited by applicant]
US 20030175334A1 · Bolton et al. · 2003 [cited by applicant]
US 20070122466A1 · Chancellor et al. · 2007 [cited by applicant]
US 20130089598A1 · Gupta · 2013 [cited by examiner]
US 20150157570A1 · Babiychuk et al. · 2015 [cited by applicant]
US 20150259382A1 · Wang · 2015 [cited by examiner]
CA 2703179 · 2009 [cited by examiner]
JP 2015519383A · 2015 [cited by applicant]
WO 2013186286A1 · 2013 [cited by applicant]
WO 2017222912A1 · 2017 [cited by applicant]
Dong, D et al in PLOS One, vol. 10, 1-16 and Jun. 2015. [cited by examiner]
Furukawa_et_al, Journal of Bacteriology, Feb. 2006, pp. 1211-1217. [cited by applicant]
Lee_et_al, Journal of Microbiol. Biotechnol, 2017, 27(6), pp. 1053-1064. [cited by applicant]
Roy et al., Virulence, 2018, vol. 9, No. 1, pp. 522-554. [cited by applicant]
Valentini et al, ScienceDirect, Current Opinion in Microbiology, 2018, 41:15-20. [cited by applicant]
International Search Report issued in International Application No. PCT/EP2018/055061, dated May 8, 2018. [cited by applicant]
Bhattacharya et al., “Prevention and treatment of Staphylococcus aureus biofilms,” Expert Rev Anti Infect Ther. 13(12):1499-1516 (2015). [cited by applicant]
Dong et al., “Distribution and Inhibition of Liposomes on [cited by applicant]
Henry et al., “Engineering liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice,” Nature Biotechnology 33(1):81-91 (2015). [cited by applicant]
Azeredo Da Silveira et al., “Liposomes as novel anti-infectives targeting bacterial virulence factors?”, Expert Review of Anti-Infective Therapy, 2015, vol. 13, No. 5, pp. 531-533. [cited by applicant]
Bjarnsholt et al., “Applying insights from biofilm biology to drug development—can a new approach be developed?”, Nat. Rev. Drug Discov., 2013, vol. 12, pp. 791-808. [cited by applicant]
Braun et al., “Pneumolysin, a Protein Toxin of Streptococcus pneumoniae, Induces Nitric Oxide Production from Macrophages”, Nfection and Immunity, vol. 67, No. 8, Aug. 1999, pp. 3750-3756. [cited by applicant]
Cai et al., “Novel Insights for Systemic Inflammation in Sepsis and Hemorrhage”, Mediators of Inflammation, vol. 2010, Article ID 642462, pp. 1-10. [cited by applicant]
Davies, “Understanding Biofilm Resistance to Antibacterial Agents”, Nat. Rev. Drug Discov., 2003, vol. 2, pp. 114-122. [cited by applicant]
Francois et al., “CAL02: a liposomal adjunctive anti-toxin therapy in infections. A new therapeutic approach for severe community-acquired pneumonia”, PowerPoint from the European Congress of Clinical Microbiology and I… [cited by applicant]
Hammond et al., “Balanced Crystalloids versus Saline in Critically III Adults—A Systematic Review with Meta-Analysis”, NEJM Evid, vol. 1, No. 2, Jan. 18, 2022, pp. 1-12. [cited by applicant]
Henry et al., “Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice,” Nature Biotechnology, 2014, vol. 33, No. 1, pp. 81-88. [cited by applicant]
Laterre et al., “CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomized trial,” Lancet Infect Dis, May 2019, vol. 19, pp. 620-630. [cited by applicant]
Lee et al., “The Hypotension Period after Initiation of Appropriate Antimicrobial Administration Is Crucial for Survival of Bacteremia Patients Initially Experiencing Severe Sepsis and Septic Shock”, J. Clin. Med., Aug.… [cited by applicant]
Peneysan et al., “Antibiotic Discovery: Combatting Bacterial Resistance in Cells and in Biofilm Communities”, Molecules, 2015, vol. 20, pp. 5286-5298. [cited by applicant]
Qu et al., “Case report of rescue of a patient with COVID-19 and shock after holmium laser lithotripsy”, Int J Urol Nurs., 2022, vol. 16, No. 03, pp. 245-251. [cited by applicant]
Rabin et al., “Biofilm formation mechanisms and targets for developing antibiofilm agents”, Future Med. Chem., 2015, vol. 7 No. 4, pp. 493-512. [cited by applicant]
Rasamiravaka et al., “The Formation of Biofilms by Pseudomonas aeruginosa: A Review of the Natural and Synthetic Compounds Interfering with Control Mechanisms”, BioMed Research International, vol. 2015, pp. 1-17. [cited by applicant]
Tracey et al., “Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia”, Nature, vol. 330, No. 6149, Dec. 17, 1987, pp. 662-664. [cited by applicant]
Tran et al., “The Pseudomonas aeruginosa Type III Translocon Is Required for Biofilm Formation at the Epithelial Barrier”, PLOS Pathogens, 2014, vol. 10 No. 11, pp. 1-11. [cited by applicant]
Weinberg et al., “Interleukin-1 and tumour necrosis factor cause hypotension in the conscious rabbit”, Clinical Science, Feb. 16, 1988, vol. 75, No. 3, pp. 251-255. [cited by applicant]
Wu et al., “Strategies for combating bacterial biofilm infections”, International Journal of Oral Science, 2015, vol. 7, pp. 1-7. [cited by applicant]
Xu et al., “Noma in a boy with septic shock: a case report”, BMC Pediatrics, 2019, vol. 19, 200, pp. 1-5. [cited by applicant]